Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VLON - GRI Bio Inc

Previous close
0   0%

Share volume: 0
Last Updated:
Pharmaceutical Preparation Manufacturing : -2.77%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
2.28%
6 Months
-43.82%
1 Year
-43.82%
2 Year
28.59%
Key data
Stock price
N/A
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.34 - $0.80
52 WEEK CHANGE
-$43.82
MARKET CAP 
9.707 B
YIELD 
N/A
SHARES OUTSTANDING 
13.482 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO:
Region: US
Website: www.vallon-pharma.com
Employees: 2
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

Recent news